Managing Symptom Burden and Optimizing Treatment Outcomes in Myelofibrosis

Managing Symptom Burden and Optimizing Treatment Outcomes in Myelofibrosis is organized by i3 Health and will be held from Jun 30, 2022 - Jun 29, 2023.,,Statement of Need:,Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia (Verstovsek et al, 2022). Though allogenic stem cell transplant is potentially curative, comorbidities preclude many patients from receiving this treatment. Therefore, therapeutic goals focus on slowing progression, managing complications, and maintaining quality of life. Currently, the discovery of the JAK-STAT pathway’s role in the pathogenesis of myelofibrosis is transforming the landscape, with novel agents that improve patients’ splenomegaly, systemic symptoms, survival, and overall quality of life (Verstovsek et al, 2022). However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians. In this activity, John Mascarenhas, MD, Professor of Medicine at Mount Sinai Icahn School of Medicine, will update learners on myelofibrosis risk stratification, novel therapies to slow disease progression and reduce symptom burden, and strategies to maintain patient quality of life.,,Learning Objectives:,Upon completion of this activity, participants should be able to,• Evaluate risk stratification criteria that can inform individualized MF management plans,• Assess emerging efficacy and safety data on novel therapies for reducing symptom burden and prolonging survival in patients with MF,• Apply strategies to optimize the safety and tolerability of novel MF therapies and optimize quality of life,,Additional details will be posted as soon as information is available.